ACTIVE-A: Cardiovascular End Points by Treatment Group

End point Clopidogrel, n (%/y) Placebo, n (%/y) Relative risk (95% CI) p
Major vascular events 832 (6.8) 924 (7.6) 0.89 (0.81-0.98) .01
Stroke 296 (2.4) 408 (3.3) 0.72 (0.62-0.83) <.001
MI 90 (0.7) 115 (0.9) 0.78 (0.59-1.03) .08

Strokes of ischemic or unknown origin were reduced significantly, and hemorrhagic stroke was increased, although not significantly.

colinhua 發表在 痞客邦 PIXNET 留言(0) 人氣()